A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors

Modern Pathology

Volumn 27, Issue 1, 2014, Pages 44-54

  Kerr, Sarah E ^a   Schnabel, Catherine A ^b   Sullivan, Peggy S ^c   Zhang, Yi ^b   Huang, Vivian J ^b   Erlander, Mark G ^b   Brachtel, Elena F ^d   Dry, Sarah M ^c  

^a MAYO CLINIC   (United States)

^b BioTheranostics Inc ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

carcinoid; classification; expression; molecular; neuroendocrine

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; CLASSIFICATION; CLASSIFIER; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL IMAGING; FEMALE; GASTROINTESTINAL TUMOR; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG SMALL CELL CANCER; LUNG TUMOR; LYMPH NODE BIOPSY; MALE; MERKEL CELL TUMOR; METASTASIS; MIDDLE AGED; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PHEOCHROMOCYTOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA; TUMOR GENE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASMS, UNKNOWN PRIMARY; NEUROENDOCRINE TUMORS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84891744474     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.105     Document Type: Article

References (83)

1. Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010;39:707-712.
2. Scarpa A, Mantovani W, Capelli P, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010;23: 824-833.
3. Anthony LB, Strosberg JR, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum. Pancreas 2010;39:767-774.
4. Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 2010;39:753-766.
5. Chen H, Sippel RS, O'Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010;39:775-783.
6. Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010;39:735-752.
7. Phan AT, Oberg K, Choi J, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas 2010;39:784-798.
8. Raymond E, Hobday T, Castellano D, et al. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer Metastasis Rev 2011;30:19-26.
9. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.
10. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76.
11. Stoyianni A, Pentheroudakis G, Pavlidis N. Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors. Cancer Treat Rev 2011;37:358-365.
12. Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 2010;39:799-800.
13. Van Eeden S, Quaedvlieg PF, Taal BG, et al. Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum Pathol 2002;33:1126-1132. (Pubitemid 35416711)
14. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist 2005;10:123-131. (Pubitemid 40261951)
15. Cheuk W, Kwan MY, Suster S, et al. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med 2001;125:228-231. (Pubitemid 32167475)
16. Bobos M, Hytiroglou P, Kostopoulos I, et al. Immunohistochemical distinction between merkel cell carcinoma and small cell carcinoma of the lung. Am J Dermatopathol 2006;28:99-104. (Pubitemid 44270868)
17. Sangoi AR, Ohgami RS, Pai RK, et al. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod Pathol 2011;24: 412-424.
18. Srivastava A, Hornick JL. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. Am J Surg Pathol 2009;33:626-632.
19. Erlander MG, Ma XJ, Kesty NC, et al. Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J Mol Diagn 2011;13: 493-503.
20. Kerr SE, Schnabel CA, Sullivan PS, et al. Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin Cancer Res 2012;30:30.
21. Ma XJ, Patel R, Wang X, et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med 2006;130:465-473.
22. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-752.
23. Pillai R, Deeter R, Rigl CT, et al. Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffinembedded specimens. J Mol Diagn 2011;13:48-56.
24. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874. (Pubitemid 32878711)
25. van Laar RK, Ma XJ, de Jong D, et al. Implementation of a novel microarray-based diagnostic test for cancer of unknown primary. Int J Cancer 2009;125:1390-1397.
26. Eiermann W, Rezai M, Kummel S, et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a riskadapted change in chemotherapy use. Ann Oncol 2012;7:7.
27. Mathieu MC, Mazouni C, Kesty NC, et al. Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy. Ann Oncol 2012;23:2046-2052.
28. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536. (Pubitemid 34130608)
29. Wick MR. Neuroendocrine neoplasia. Current concepts. Am J Clin Pathol 2000;113:331-335.
30. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20: 2633-2642. (Pubitemid 34575635)
31. Nakagawa T, Tanaka Y, Matsuoka E, et al. Identification and classification of 16 new kinesin superfamily (KIF) proteins in mouse genome. Proc Natl Acad Sci USA 1997;94:9654-9659. (Pubitemid 27408117)
32. Wang W, Jiang Q, Argentini M, et al. Kif2C minimal functional domain has unusual nucleotide binding properties that are adapted to microtubule depolymerization. J Biol Chem 2012;287:15143-15153.
33. Yoshida K. Cell-cycle-dependent regulation of the human and mouse Tome-1 promoters. FEBS Lett 2005; 579:1488-1492. (Pubitemid 40289200)
34. Katoh M. Characterization of KIF12 gene in silico. Oncol Rep 2005;13:367-370.
35. Lee NP, Poon RT, Shek FH, et al. Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma. Biochim Biophys Acta 2010;1806:138-145.
36. Morimatsu K, Aishima S, Kayashima T, et al. Liverintestine cadherin expression is associated with intestinal differentiation and carcinogenesis in intraductal papillary mucinous neoplasm. Pathobiology 2012;79:107-114.
37. Park JH, Seol JA, Choi HJ, et al. Comparison of cadherin-17 expression between primary colorectal adenocarcinomas and their corresponding metastases: the possibility of a diagnostic marker for detecting the primary site of metastatic tumour. Histopathology 2011;58:315-318.
38. Wang J, Yu JC, Kang WM, et al. The predictive effect of cadherin-17 on lymph node micrometastasis in pN0 gastric cancer. Ann Surg Oncol 2012;19:1529-1534.
39. Xu Y, Zhang J, Liu QS, et al. Knockdown of liverintestine cadherin decreases BGC823 cell invasiveness and metastasis in vivo. World J Gastroenterol 2012;18: 3129-3137.
40. Voth H, Oberthuer A, Simon T, et al. Identification of DEIN, a novel gene with high expression levels in stage IVS neuroblastoma. Mol Cancer Res 2007;5: 1276-1284.
41. Voth H, Oberthuer A, Simon T, et al. Co-regulated expression of HAND2 and DEIN by a bidirectional promoter with asymmetrical activity in neuroblastoma. BMC Mol Biol 2009;10:28.
42. Cai LY, Abe M, Izumi S, et al. Identification of PRTFDC1 silencing and aberrant promoter methylation of GPR150, ITGA8 and HOXD11 in ovarian cancers. Life Sci 2007;80:1458-1465. (Pubitemid 46399750)
43. Goodman FR. Limb malformations and the human HOX genes. Am J Med Genet 2002;112:256-265.
44. Patterson LT, Pembaur M, Potter SS. Hoxa11 and Hoxd11 regulate branching morphogenesis of the ureteric bud in the developing kidney. Development 2001;128:2153-2161. (Pubitemid 32600475)
45. Taketani T, Taki T, Shibuya N, et al. The HOXD11 gene is fused to the NUP98 gene in acute myeloid leukemia with t(2;11)(q31;p15). Cancer Res 2002;62:33-37. (Pubitemid 34073981)
46. Zha Y, Ding E, Yang L, et al. Functional dissection of HOXD cluster genes in regulation of neuroblastoma cell proliferation and differentiation. PLoS One 2012;7:e40728.
47. Bellefroid EJ, Kobbe A, Gruss P, et al. Xiro3 encodes a Xenopus homolog of the Drosophila Iroquois genes and functions in neural specification. EMBO J 1998;17:191-203. (Pubitemid 28041060)
48. Ragvin A, Moro E, Fredman D, et al. Long-range gene regulation links genomic type 2 diabetes and obesity risk regions to HHEX, SOX4, and IRX3. Proc Natl Acad Sci USA 2010;107:775-780.
49. Hill VK, Dunwell TL, Catchpoole D, et al. Frequent epigenetic inactivation of KIBRA, an upstream member of the Salvador/Warts/Hippo (SWH) tumor suppressor network, is associated with specific genetic event in B-cell acute lymphocytic leukemia. Epigenetics 2011;6:326-332.
50. Ji M, Yang S, Chen Y, et al. Phospho-regulation of KIBRA by CDK1 and CDC14 phosphatase controls cellcycle progression. Biochem J 2012;447:93-102.
51. Kauppi K, Nilsson LG, Adolfsson R, et al. KIBRA polymorphism is related to enhanced memory and elevated hippocampal processing. J Neurosci 2011;31: 14218-14222.
52. Makuch L, Volk L, Anggono V, et al. Regulation of AMPA receptor function by the human memoryassociated gene KIBRA. Neuron 2011;71:1022-1029.
53. Shinawi T, Hill V, Dagklis A, et al. KIBRA gene methylation is associated with unfavorable biological prognostic parameters in chronic lymphocytic leukemia. Epigenetics 2012;7:211-215.
54. Greer JM, Capecchi MR. Hoxb8 is required for normal grooming behavior in mice. Neuron 2002;33:23-34. (Pubitemid 34088176)
55. Knoepfler PS, Sykes DB, Pasillas M, et al. HoxB8 requires its Pbx-interaction motif to block differentiation of primary myeloid progenitors and of most cell line models of myeloid differentiation. Oncogene 2001;20:5440-5448. (Pubitemid 32889480)
56. Vider BZ, Zimber A, Hirsch D, et al. Human colorectal carcinogenesis is associated with deregulation of homeobox gene expression. Biochem Biophys Res Commun 1997;232:742-748. (Pubitemid 27214069)
57. Adesina AM, Nguyen Y, Guanaratne P, et al. FOXG1 is overexpressed in hepatoblastoma. Hum Pathol 2007; 38:400-409. (Pubitemid 46227532)
58. Adesina AM, Nguyen Y, Mehta V, et al. FOXG1 dysregulation is a frequent event in medulloblastoma. J Neurooncol 2007;85:111-122. (Pubitemid 47629393)
59. Dastidar SG, Narayanan S, Stifani S, et al. Transducinlike enhancer of Split-1 (TLE1) combines with Forkhead box protein G1 (FoxG1) to promote neuronal survival. J Biol Chem 2012;287:14749-14759.
60. Kortum F, Das S, Flindt M, et al. The core FOXG1 syndrome phenotype consists of postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and corpus callosum hypogenesis. J Med Genet 2011;48:396-406.
61. Striano P, Paravidino R, Sicca F, et al. West syndrome associated with 14q12 duplications harboring FOXG1. Neurology 2011;76:1600-1602.
62. Tian C, Gong Y, Yang Y, et al. Foxg1 has an essential role in postnatal development of the dentate gyrus. J Neurosci 2012;32:2931-2949.
63. Gutierrez A, Kentsis A, Sanda T, et al. The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood 2011;118:4169-4173.
64. Obata M, Kominami R, Mishima Y. BCL11B tumor suppressor inhibits HDM2 expression in a p53-dependent manner. Cell Signal 2012;24:1047-1052.
65. Zhang LJ, Vogel WK, Liu X, et al. Coordinated regulation of transcription factor Bcl11b activity in thymocytes by the mitogen-activated protein kinase (MAPK) pathways and protein sumoylation. J Biol Chem 2012;287:26971-26988.
66. Long KB, Srivastava A, Hirsch MS, et al. PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol 2010;34:723-729.
67. Medeiros F, Rigl CT, Anderson GG, et al. Tissue handling for genome-wide expression analysis: a review of the issues, evidence, and opportunities. Arch Pathol Lab Med 2007;131:1805-1816. (Pubitemid 350294581)
68. Guerriere-Kovach PM, Hunt EL, Patterson JW, et al. Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes. Am J Clin Pathol 2004;122: 70-77. (Pubitemid 38849874)
69. Montone KT, van Belle P, Elenitsas R, et al. Protooncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 1997;10:939-944. (Pubitemid 27431970)
70. Leong TY, Cooper K, Leong AS. Immunohistology-past, present, and future. Adv Anat Pathol 2010;17: 404-418.
71. Bussolati G, Leonardo E. Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol 2008;61:1184-1192.
72. Leong AS. Pitfalls in diagnostic immunohistology. Adv Anat Pathol 2004;11:86-93.
73. Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol 2000; 13:238-242. (Pubitemid 30207508)
74. Kubba LA, McCluggage WG, Liu J, et al. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod Pathol 2008;21:485-490. (Pubitemid 351441040)
75. D'Alessandro V, Muscarella LA, la Torre A, et al. Molecular analysis of the HuD gene in neuroendocrine lung cancers. Lung Cancer 2010;67:69-75.
76. Lee EK, Kim W, Tominaga K, et al. RNA-binding protein HuD controls insulin translation. Mol Cell 2012;45:826-835.
77. Binda AV, Kabbani N, Levenson R. Regulation of dense core vesicle release from PC12 cells by interaction between the D2 dopamine receptor and calciumdependent activator protein for secretion (CAPS). Biochem Pharmacol 2005;69:1451-1461. (Pubitemid 40602445)
78. Hooks SB, Callihan P, Altman MK, et al. Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells. Mol Cancer 2010;9:289.
79. James MA, Lu Y, Liu Y, et al. RGS17, an overexpressed gene in human lung and prostate cancer, induces tumor cell proliferation through the cyclic AMP-PKA-CREB pathway. Cancer Res 2009;69: 2108-2116.
80. Sun Y, Fang R, Li C, et al. Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro. Biochem Biophys Res Commun 2010;396:501-507.
81. Bonnefond A, Philippe J, Durand E, et al. Wholeexome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene. PLoS One 2012;7:e37423.
82. Dupont J, Pereira C, Medeira A, et al. Permanent neonatal diabetes mellitus due to KCNJ11 mutation in a Portuguese family: transition from insulin to oral sulfonylureas. J Pediatr Endocrinol Metab 2012;25:367-370.
83. Rubio-Cabezas O, Flanagan SE, Damhuis A, et al. KATP channel mutations in infants with permanent diabetes diagnosed after 6 months of life. Pediatr Diabetes 2012;13:322-325.